COVID-19 and nutriceutical therapies, especially using zinc to supplement antimicrobials

Abstract

The nutritional status of a patient can be critical for the efficacy of other pharmaceuticals, especially organic antibiotics, to treat viral pandemics. There may be political and scientific difficulties in achieving a constructive synergy of nutritional and prescribed allopathic remedies. For adequate treatment, timelines may need to extend well beyond eliminating viral proliferation, e.g., with vaccines, to include the goals of (a) reducing post-viral fatigue, (b) promoting earliest recovery, and (c) future resistance in often poorly nourished patients, e.g., obese (!). Many trace minerals (TM) and vitamins may need to be replenished. This review focusses only upon zinc to illustrate some problems in rectifying these TM deficiencies affecting the balance between continued ill-health (‘illth’) or regaining optimal physical and mental wellbeing. Ultimately, this is a matter of behaviour, lifestyle, and informed choice(s). See Hetzel and McMichael 1959.

“Epidemics are no accidents. A new pathogen will enter a community only when the conditions are ripe for it..”

Nathan Clumek, Brussels (Cribb 1996).

Preamble

This commentary describes some of the problems when practising Integrated Medicine, combining the wisdom of Food Science and Dietetics (FSD) with that of experimental therapeutics. We hear and read much about the latter (it makes money), rather less about the former (FSD) and almost nothing about their synergistic interactions, except when they have adverse effects (fortunately rare)! All that may change as we try to focus on novel approaches for treating the current widespread pandemic presenting as severe acute respiratory syndrome (SARS-2) aka COVID-19. Its lethality often involves a ‘cytokine storm’ induced as an over-reaction by the host’s immune system, overwhelming the patient’s resistance. By historical standards, it is one of the lighter pandemics, but still especially dangerous for certain populations: the elderly, the obese and those lacking effective levels of Type 1-interferons.

Therapy

Since its massive outbreak in 2019 (Chan et al. 2020), a large number of drug candidates have been evaluated as possible inhibitors for this RNA coronavirus. Rather surprisingly, a few of the more promising candidates have not hitherto been classified as antivirals. They include two conventional but quite unrelated anti-infective agents, namely, hydroxychloroquine (HCQ), Plaquenil™, and Ivermectin (IMN) Mectizan^R. When used with a zinc supplement, they may acquire significant anti-viral activity.

HCQ is a synthetic analogue of quinine, available since 1951 to treat malaria, a protozoal disease. It is currently used as a relatively safe anti-rheumatic and to suppress systemic lupus erythematosus (Rainsford et al. 2015). It has been derided on political grounds (Table 1) even rejected, because it does not seem to provide consistent benefits when compared between different trials. This is a very important observation, but needs some answers to ancillary and pertinent questions relating to the status of patients entering clinical trials (age, genetics, obesity, metabolic syndrome and other co-morbidities, drug clearance rates, possible dietary antagonists, etc.) and especially the nutritional and/or immunological status of the affected patients.

Table 1 Zinc, an adjunct therapy for viral life-threatening infections

IMN (MK933) is used as an anti-helmintic to prevent ‘river blindness’, onchocerciasis in West Africa¹ and Latin America, caused by a filarial nematode (Campbell 1989). It is the second leading cause of blindness, after trachoma. IMN is on the WHO’s list of essential medicines.

It also controls COVID-19 infections when used in combination with zinc (Borody and Hazan 2020). Dexamethasone and a number of conventional antibiotics, e.g., doxcycline, clarithromycin, azithromycin, etc., have been considered for trials in COVID-19 clinics. Azithromycin may have particular advantages for use in lung inflammation and congestive conditions because of its unique ability to accumulate in lung parenchyma and mucosa and stimulate interferons (Menzel et al. 2016) [This list will probably grow considerably in the near future.] Their efficacy may also be conditioned by nutritional factors and the patient’s immunological status.

Zinc status

This has often been neglected (Table 2) in treating patients or adjusting their therapies, not only for treating COVID-19 but many other disorders needing more adequate nutritional support. Zinc deficiency is associated with aging (Prasad 1993) and a wide range of medical disorders (n≥22), congenital birth defects (n≥15), and degenerative diseases of all age groups (Wallach and Lan 1999). In the context of the COVID-19 pandemic, zinc repletion may be essential for:

Table 2 Some problems (and queries) about using zinc in crisis medicine

• i. (Intrinsic) anti-viral activity (Chasapis et al. 2012; Read et al. 2019; Skalny et al. 2020)

• ii. Moderating the host’s response, the cytokine storm, e.g., inhibiting the biogenesis of TNF-alpha and IL-1 beta (Prasad et al. 2011).

• iii. Stimulating early recovery in dual roles of (a) hel** combat post-viral depression through some known—and other still unknown—effects on the brain (Pfeiffer and Banks 1982) and the immune system; and (b) repair and restoration of function, especially in the lung; zinc being an essential nutrient for renewed nucleic acid and protein synthesis.

• iv. Strengthening host resistance by replenishing depleted zinc reserves in the liver, circulating leukocytes and skeletal tissues.

Chloroquine (and HCQ) may support these activities acting as ionophores assisting (a) zinc distribution to critical responsive sites in the body’s tissues and (b) perhaps also withholding zinc from replicating intracellular virus articles. Other zinc-binding molecules, particularly thiols such as N-acetylcysteine (but not d-penicillamine), might be useful adjuncts during intensive therapy.

Obesity

Many clinicians have observed the high mortality from COVID-19 in their obese patients (Popkin et al. 2020; Rebello et al. 2020; Richardson et al. 2020; Sanchis-Gomar et al. 2020; Lockhart and O’Rahilly 2020). Over 80% of obese people may compulsively over-eat caused by chronic hunger as their bodies seek essential dietary minerals, lacking in their normal, but impoverished diet. [This is known as ‘pica’ (Latin for ‘magpie’) = an abnormal craving for clays, soils from termite mounds (sic) and other sources of essential trace minerals, e.g., iron, zinc, etc.] This geophagy or geopharmacy is extensively practised by impoverished pregnant women in the Third World (Root-Bernstein 1997; Kambunga et al. 2019). It is a testimony to the need for mineral supplements to support health and combat malnutrition.

Zinc supplements may reduce the weight, body mass index, and waist and hip circumference in obese individuals (Khorsanda et al. 2019). From this limited database, two lessons seem to be (1) effective zinc repletion can overcome previous zinc depletion, often chronic before the pandemic but enhanced by rapid viral proliferation; (2) it may take time to adequately restore/renormalise the body’s zinc reserves.

A considerable proportion (≤25%) of COVID-19 patients in recovery phase suffer prolonged post-viral symptoms including mental distress (Garner 2020). Sustained zinc repletion may be needed during this non-lethal second phase of the pandemic.

Other comments

• 1. Concerning nutritional status:

Some facets of this commentary may apply to several anti-inflammatory, antioxidant, and immunostimulant trace elements, e.g., copper, zinc, selenium, other essential nutrients, and many vitamins, e.g., B₆. They are all exogenous to the body and must be efficiently ingested from the diet or supplied parenterally.

Three quotes from Carl Pfeiffer writing 40 years ago are still so pertinent today:

• “If only doctors were urged to participate in nutritional guidance, if only they’d become more interested in nutrition….”

• “Orthomolecular medicine (biochemical medicine) is simply the correction of faulty biochemistry, with the right molecules or essential nutrients given at the right time.”

• “A preventive program is far more effective than the use of drugs against symptoms.” (Pfeiffer and Banks 1982)

• 2. Concerning early trials of alternative non-vaccine treatments for COVID-19. Some conclusions from certain recent trials of potential therapies have been sharply criticised, their methodologies seeming inadequate and their conclusions questionable (Bramstedt 2020). If the dietary and immunological status of the patients were more fully evaluated before and after the treatments, we might find that personalised corrective therapies (e.g., nutritional, immunostimulant, etc.) are just as important as prescribing any new or rediscovered anti-viral drug.

• 3. Planned nutrition is now becoming respectable medicine again (BourBour et al. 2020; Polamarasetti and Martirosyan 2020) as it certainly was half a century ago.

• 4. Final suggestions. Improving the zinc status of COVID-19 patients should help to both conquer the infection and bolster their recovery. Other nutrients should also be considered when adopting this health-restoration strategy.

Appendix

• An intriguing ‘blast from the past’ is provided by two observations on the properties of chloroquine (the chronological precursor of hydroxychloroquine): (i) chloroquine manifests many anti-inflammatory effects, disclosed by experimental studies over a wide range of in vitro and in vivo assays (Swingle 1974); (ii) a zinc-deficiency disease in chickens presents as a form of polyarthritis, that is corrected by administering chloroquine (Hoekstra 1969). Even 50 years later, poultry scientists are still very concerned about zinc nutrition as ‘preventive medicine’ (Naz et al. 2016).

  The journal Frontiers in Public Health has published some important reviews including treating COVID-19 by dietary changes (Chaari et al. 2020). The companion journal Frontiers in Pharmacology has discussed therapeutic options under investigation (Kaddoura et al. 2020).